Laureaten van de projectoproep "Wetenschappelijke Grants 2022"
Dankzij de vrijgevigheid van haar donateurs financiert Stichting tegen Kanker dit jaar 57 projecten van verschillende oncologische onderzoeksinstellingen in het land, voor een totaalbedrag van 25,7 miljoen euro.
Deze projecten hebben tot doel de ziekte beter te begrijpen, de genezingskansen verder te vergroten en de levenskwaliteit van mensen met kanker te verbeteren.
De financiering van het Belgisch wetenschappelijk kankeronderzoek is al meer dan 30 jaar de prioritaire missie van Stichting tegen Kanker. Door het meest innovatieve kankeronderzoek te financieren, helpen we hoop om te zetten in overwinning.
De laureaten van de selectie door de onafhankelijke wetenschappelijke raden zijn de volgende:
Fundamenteel onderzoek : 29 projecten - € 14 294 198
Onderzoeksteam(s)
Organisatie(s)
Bedrag
Type van kanker
Type van behandeling
Titel van het project
Agostinis Patrizia
KU Leuven
350 000 €
Melanoom
Harnessing lysosomal iron homeostasis to prevent melanoma dissemination
Beck Benjamin
ULB
598 000 €
Slokdarmkanker
A cellular reservoir for metaplasia and cancer initiation in the oesophagus
Callewaert Nico
UGent
359 999 €
Celtherapie
Arming therapeutic CAR-T cells with glyco-engineered suppressors of tumor-infiltrating regulatory T cells
Constantinescu Stefan
De Duve Instituut
600 000 €
Leukemie
Role of the Human Thrombopoietin Receptor in Myeloproliferative Neoplasms and transition to Secondary Acute Myeloid Leukemia.
Corbet Cyril
UCLouvain
580 000 €
Hoofd- en halskanker
Towards metabolic targeting of the minimal residual disease in head and neck cancers
De Smet Frederik & Vermeirssen Vanessa & Quintens Roel
KU Leuven & UGent & Belgian Nucleair Research Centre
480 000 €
Hersenkanker
Radiotherapie
Targeting radiation-induced plasticity in Glioblastoma: from fundamental insights to tailored therapeutic opportunities
Dierickx Daan
KU Leuven
400 000 €
Lymfoom
Molecular characterization of hyperactive T cell receptor signaling in peripheral T cell lymphoma to uncover druggable targets
Elewaut Dirk
UGent
475 000 €
Leverkanker
Role of endogenous NKT ligands induced by Endoplasmic Reticulum stress in NASH-driven hepatocellular carcinoma
Elia Ilaria
KU Leuven
336 000 €
Huidkanker
Potentiating the metabolic fitness of metastasis associated CD8+ T cells through spatial metabolomics.
Fendt Sarah-Maria
KU Leuven
600 000 €
Borstkanker
Lipid metabolism in obesity and aging-induced cancer metastasis
Gilles Christine
ULiège
360 000 €
Studying Tissue Factor-dependent membrane protein proteolysis in metastasis
Goossens Steven
UGent
480 000 €
Leukemie
Oncogenic Role of SOX11 in T-cell acute lymphoblastic leukemia
Goriely Stanislas
ULB
478 400 €
Immunotherapie
Targeting Heme Oxygenase-1 expressing tumor associated macrophages to improve cancer immunotherapy
Gurzov Esteban & Verslype Chris & Scott Charlotte
ULB & KU Leuven & UGent
480 000 €
Leverkanker
Obesity-associated Hepatocellular Carcinoma at Single Cell Resolution for Risk Prediction and Novel Therapeutics - HepatoSCRIPT
Marine Jean-Christophe
KU Leuven
600 000 €
Huidkanker
Detection and prevention of early metastatic dissemination of melanoma
Mestdagh Pieter
UGent
510 000 €
Immunotherapie
Identifying lncRNA modulators of T-cell activation to enhance immune-checkpoint inhibition therapy
Movahedi Kiavash
VUB
478 000 €
Hersenkanker
Immunotherapie
Macrophage-based cell therapy for brain cancer
Noel Agnès
ULiège
600 000 €
Targeting ferroptosis resistance of metastasizing cancer cells in lymph node
Pastushenko Ievgenia
ULB
600 000 €
Defining the role of the frequently mutated epigenetic regulators in cancer
Rooman Ilse & Van Laethem Jean-Luc
VUB & ULB
476 800 €
Pancreaskanker
InterCePPT: Interfere with Cellular Positioning in the Pancreatic Tumor
Speleman Franki
UGent
600 000 €
Neuroblastoom
Single-cell and spatial multi-omics exploration of tumor intrinsic and microenvironment responses to ALK-ATR-CHK1-RRM2 axis drugging in neuroblastoma
Tissir Fadel
UCLouvain
600 000 €
Hersenkanker
Glioblastoma prognosis and treatment: Could DIAPH3 be a game-changer?
van der Bruggen Pierre
Institut de Duve
360 000 €
Immunotherapie
Cancer-associated neutrophils and their impact on immune cells
Van Keymeulen Alexandra
ULB
369 600 €
Borstkanker
Deciphering the cell plasticity preceding tumor appearance in the mammary gland
van Loo Geert
UGent
480 000 €
Huidkanker
The impact of cell death on the cancer stem cell niche in non-melanoma skin cancer
Van Vlierberghe Pieter
UGent
600 000 €
Leukemie
PU.1 as driver of leukemic stem cells in human T cell acute lymphoblastic leukemia
Vanden Berghe Tom
UAntwerpen
462 400 €
Neuroblastoom
Studying the epigenetic regulation of ferroptosis in high-risk neuroblastoma
Translationeel en klinisch onderzoek:
21 projecten - € 9 557 935
Onderzoeksteam(s)
Organisatie(s)
Bedrag
Type van kanker
Type van behandeling
Titel van het project
Baron Frédéric & Humblet-Baron Stéphanie & Marchant Arnaud
ULiège & KU Leuven & ULB
600 000 €
Leukemie
Systems Vaccinology in allogeneic hematopoietic stem cell transplant recipients
Blanpain Cédric
ULB
600 000 €
Longkanker
Defining and targeting tumor cell states responsible for resistance to therapy
Buisseret Laurence
Institut Jules Bordet
300 00 €
Borstkanker
Immunotherapie
Impact of immunotherapy on triple-negative breast cancer microenvironement
Ceelen Wim & Van Ginderachter Jo
UGent & VUB
512 500 €
Dikkedarmkanker
Immunotherapie
Engineering the tumor immune microenvironment in colorectal peritoneal metastases by locoregional delivery of toll like receptor agonists
De Geest Bruno & Laoui Damya
UGent & VUB
450 000 €
Immunotherapie
A translational cancer vaccination approach based on co-delivery of tumor antigen and Toll-like receptor agonists
De Moerloose Barbara
UGent
300 000 €
Leukemie
Integration of genome, epigenome, and transcriptome in juvenile myelomonocytic leukemia and functional analysis of circular RNAs as novel biomarker and/or therapeutic targets
De Preter Katleen
UGent
588 238 €
Huid-, long- en nierkanker
Immunotherapie
NIPITplus, a multi-cancer blood test to predict immune checkpoint inhibitor response and monitor toxicity
De Wever Olivier
UGent
400 000 €
Sarcoom
Exploiting patient-derived models to guide therapeutic decision making in soft tissue sarcoma
Desmedt Christine
KU Leuven
598 970 €
Borstkanker
MetLob: A post-mortem tissue donation study dedicated to Metastatic Lobular breast cancer
Flamen Patrick
Institut Jules Bordet
299 345 €
Pancreas en dikkedarmkanker
Doelgerichte therapie
Lu-177-FAPI (fibroblast activation protein inhibitor) radioligand therapy in colorectal and pancreatic cancers: Phase 1 study based on dosimetric rationale
Jacobs Sandra & Van Damme An
BSPHO
400 000 €
Hersenkanker
Prospective international phase-III trials to improve treatment effectiveness and quality of survival in children with embryonal brain tumours
Lambrecht Maarten & De Saint Hubert Marijke
UZ Leuven & SCK CEN
523 047 €
Radiotherapie
ProPOSE: Proton therapy in Pregnancy for Optimal, Safe and Effective cancer treatment
Michaux Lucienne
UZ Leuven
448 284 €
Lymfoom
Improved Cytogenomic Diagnosis in Lymphoma: Opportunities of Optical Genome Mapping and Long-read Sequencing
Nuyts Sandra & Nevens Daan
UZ Leuven & UZ Antwerpen
400 000
Hoofd- en halskanker
Radiotherapie en immunotherapie
PROLoNg-trial: Pembrolizumab and Radiotherapy for OLigometastatic squamous cell carcinoma of the head and Neck cancer: a randomized phase III study
Peeters Marc & Verslype Chris
UZ Antwerpen & KU Leuven
549 874 €
Neuro-endocriene neoplasie (NEN)
Impact of ccfDNA on clinical decision making in NEN patients
Saussez Sven & Verset Laurine
Université de Mons & Institut Jules Bordet
239 677 €
Hoofd- en halskanker
Radiotherapie
Development of a targeted theranostic platform combining magnetic nanoparticles and radiotherapy for head and neck cancer treatment
Sotiriou Christos
Institut Jules Bordet
600 000 €
Borstkanker
Decoding metastatic breast cancer heterogeneity using spatial transcriptomics and AI in the AURORA study
Tejpar Sabine
KU Leuven
449 500 €
Dikkedarmkanker
Using mucins as friends in colorectal cancer diagnostics and treatment
Van den Eynde Marc
UCLouvain
249 500 €
Dikkedarmkanker
Dimensional characterization of immune and T cells population in metastatic colorectal cancer for the development of circulating immune biomarker.
Van de Veken Pieter
UAntwerpen
450 000 €
Dikkedarmkanker
Diagnostic and theranostic targeting of fibroblast activation protein (FAP) with gold nanoparticles decorated with FAPIs and FAPI fragments.
Asbest : 7 projecten - € 1 943 370
Onderzoeksteam(s)
Organisatie(s)
Bedrag
Onderzoeksthema
Titel van het project
Bisteau Xavier
ULB
245 000 €
Mesothelioom en doelgerichte therapie
Exploiting the sensitivity of malignant pleural mesothelioma to CDK4 inhibitory drugs
Cataldo Didier
ULiège
200 000 €
Mesothelioom en doelgerichte therapie
CCL5-CCR5 axis : a therapeutic target in cisplatin resistant mesothelioma?
Gevaert Kris & Lamote Kevin
UGent & UAntwerpen
249 350 €
Mesothelioom
Validation of a protein biomarker panel in exhaled breath condensate
Huaux François
UCLouvain
313 600 €
Mesothelioom
Syndecan-1-expressing macrophages: a new immunosuppressive entity in fibre-induced cancer
Meylan Etienne
ULB
375 420 €
Mesothelioom
Analyses of the tumor immune compartment and tumor-associated neutrophils in new generation mouse models of malignant mesothelioma
Willems Luc
ULiège
240 000 €
Mesothelioom
Eosinophils propel extracellular traps on mesothelioma cells and inhibit chemoimmunotherapy
